Laidlaw acts as Exclusive Introducing Broker on NLS Pharmaceutics’ Closing of Initial Tranche of US$10.0 Million Purchase Agreement with BVF Partners L.P.
On December 14, 2022, NLS Pharmaceutics (NASDAQ:NLSP,)(NASDAQ:NLSPW) announced the closing of its previously publicized purchase agreement with BVF Partners L.P. ("BVF") comprised of an initial closing of $10 million in exchange for 11,494,253 common shares (or equivalents), Read More...
Laidlaw Capital Markets is Co-Manager in Guggenheim Active Allocation Fund Initial Public Offering
Laidlaw Capital Markets is pleased to have Co-Managed the $655,000,000 Guggenheim Active Allocation Trust offering alongside Bank of America, Morgan Stanley, & Wells Fargo.
Laidlaw Capital Markets is Co-Manager in Blackrock ESG Capital Allocation Trust $2,040,000,000 Initial Public Offering
Laidlaw Capital Markets is pleased to have Co-Managed the $2,040,000 Blackrock ESG Capital Allocation Trust offering alongside Bank of America, Morgan Stanley, UBS, & Wells Fargo
Laidlaw Capital Markets is Lead Manager in aTyr Pharma’s (LIFE) $86,250,000. Offering.
Laidlaw Capital Markets is pleased to have Lead Managed aTyr Pharma's (LIFE) $86,250,000. Offering alongside Piper Sandler and RBC. Read Article: https://investors.atyrpharma.com/news-releases/news-release-details/atyr-pharma-announces-pricing-75-million-public-offering-common
Laidlaw Capital Markets is Financial Advisor on EyePoint Pharmaceuticals Inc’s $115,400,000 Follow-On Offering.
Laidlaw Capital Markets is pleased to be Financial Advisor on the EyePoint Pharmaceutical Inc’s $115,400,000 Follow-On Offering alongside Cowen and Guggenheim Securities
Laidlaw Capital Markets is Co-Manager in Guggenheim Active Allocation Fund Initial Public Offering
Laidlaw Capital Markets is pleased to have Co-Managed the $655,000,000 Guggenheim Active Allocation Trust offering alongside Bank of America, Morgan Stanley, & Wells Fargo.
Stay In Touch